I am interested in a position posted selling Benlysta. I currently call on Rhem, and would like to learn more about this position that is open. Any thoughts on the product, position, if this is a good move?
Simple answer is NO. Crap product that has marginal benefit. Believe it or not but a Moroccan R&D exec convinced a dimwitted CEO that this was a great purchase for $3 billion. That's one of many reasons why both are being forced into retirement